TrialCardiovascular diabetology2026

Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.

Arne Gessner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.